BIOGIPUZKOAN LAN EGIN ETA ELKARREKIN BIZI
Lantoki berri batera iristean, jendea zerbait galduta senti daiteke. Edo denbora bat lanean daramanean, agian ez ditu gauzak gogoratzen edo ez ditu berriak ezagutzen. Horrela, eta HRS4R giza baliabideen kudeaketako bikaintasun-estrategiaren barruko ekintzei jarraituz, hilero ongietorria ematen jarraituko diegu Biogipuzkoako lantaldean sartzen diren pertsona berriei, eta gure Institutuan oinak jartzean
ANIMALIATEGIA BERREGITURAKETARI BURUZKO INFORMAZIO-BILERA
Animaliategiaren eraberritzeak amaitu dira, eta bilera batera deitu nahi zaituztegu animaliategia nola berregituratu den eta lan-fluxuak zein izango liratekeen azaltzeko.
Radiation-induced DNA Damage Response in Myogenic Cells
DNA is the major target of radiation therapy of malignant tumors. Amongst ionizing-radiation (IR)-induced DNA damage, DNA double-strand breaks (DSBs) are one of the most severe DNA lesions a cell can incur, leading to cell death. Despite the day-by-day improvements of cancer diagnosis and treatments, tumor-neighboring healthy tissues are still
2024/2025 ikasturtearen hasiera dibulgazio eta prestakuntzan
2024/2025 ikasturtean aurreikusten ditugun dibulgazio- eta prestakuntza-jarduerak eta berritasunak aurkeztuko ditut solasaldi honetan, kultura zientifikoz betetako ikasturte berri bati hasiera emateko.
Targeting TDP-43 splicing repression for ALS-FTD: mechanism-based gene therapy and fluid biomarker
Recent human studies strongly support the view that loss of TDP-43 splicing repression underlies the pathogenesis of ALS-FTD, a disorder spectrum currently without disease modifying therapy. To address this unmet need, we employ an AAV gene therapy approach to complement the loss of TDP-43 by delivering a novel splicing repressor
Calcium-Dependent Disruption of Skeletal Muscle Excitation-Contraction Coupling During Chemotherapy
In 2024, there will likely be 20 million new cancer cases (approximately 10 million cancer deaths) worldwide. While anti-cancer drugs like doxorubicin (DOX) are beneficial, they often induce off-target effects such as skeletal muscle fatigue and weakness. These myopathies affect up to 80% of cancer patients, persisting long after treatment
.
.
.
.
.
.
.
.
